Table 4.
Main characteristics and findings of the eligible studies included in this meta-analysis
| Reference (first author, year) | Region | Ethnic group | Controls source | Samples (N) | Cases | Controls | Polymorphic sites | HWE status† | Genotyping method | Findings |
|---|---|---|---|---|---|---|---|---|---|---|
| Liu, 2010 [35] | Taiwan | Asian | Hospital based | 496 | 249 | 247 | rs11730582, rs11439060 | Yes | TaqMan genotyping assay | rs11439060 of SPP1 promoter associated with risk of UL in allelic and genotypic models |
| Safarinejad, 2013 [19] | Iran | Asian | Population based | 1026 | 342 | 684 | rs2853744, rs11730582 | Yes | PCR-FRET | SPP1 SNP rs2853744 showed significant association with UL |
| Xiao, 2016 [20] | China | Asian | Population based | 480 | 230 | 250 | rs11730582, rs11439060 | Yes | TaqMan genotyping assay | rs11439060 in SPP1 promoter significantly associated with risk of UL as well as clinical characteristics in UL |
| Present study, 2018 | Pakistan | Asian | Population based | 478 | 235 | 243 | rs2853744, rs11730582 and rs11439060 | Yes | Sanger sequencing | All 3 SPP1 promoter SNPs associated with UL under different genetic models |
†Yes indicates consistence with HWE
FRET Fluorescence resonance energy transfer; HWE Hardy-Weinberg equilibrium; N Total number of samples; SPP1 Osteopontin; SNP Single-nucleotide polymorphism; UL Urolithiasis